Table 4.
Strain-specific A/Salomon Islands/3/2006 (H1N1), A/Brisbane/10/2007 (H3N2) and B/Florida/4/2006 (B/Florida) hemagglutination inhibition titers, seroconversion factor, seroconversion rate, and seroprotection rate
| |
H1N1 |
H3N2 |
B/Florida |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Day 0 | Day 30 | Day 0 | Day 30 | Day 0 | Day 30 | ||||
|
Seroprotection ratea (%) |
|
|
|
|
|
|
|
|
|
|
JIA (44) |
21/43 (48.8) |
|
44(100) |
20/43 (46.5) |
|
40(91) |
20/43 (46.5) |
|
42(95) |
|
Healthy children# (10) |
7(70) |
|
10(100) |
6(60) |
|
8(80) |
5(50) |
|
10(100) |
|
Seroconversion rateb (%) |
|
|
|
|
|
|
|
|
|
|
JIA |
|
|
40/43(93) |
|
|
32/43 (74.4) |
|
|
31/40 (77.5) |
|
Healthy children |
|
|
7/7(100) |
|
|
3/8 (37.5) |
|
|
6/8 (75) |
|
Seroconversion factorc |
|
|
|
|
|
|
|
|
|
|
JIA |
|
|
16.5 |
|
|
5.2 |
|
|
7.2 |
| Healthy children | 9.8 | 3.0 | 4.0 | ||||||
To meet the Committee for Proprietary Medicinal Products (CPMP) guidelines each of the vaccine antigens must meet at least one of the following criteria: seroprotection rate exceeding 70%, seroconversion rate exceeding 40%, and seroconversion factor exceeding 2.5. a Seroprotection rate: the percentage of vaccine recipients with a serum HI titres of at least 1:40 after vaccination. bSeroconversion rate: the percentage of vaccine recipients with an increase in serum HI titres by at least a factor of 4 after vaccination. c Seroconversion fator: the fold increase in serum geometric mean HI titres after vaccination.